This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Atreca's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 11.8% annually.

Anahtar bilgiler

-14.6%

Kazanç büyüme oranı

51.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-908.6%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2023

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Gelir ve Gider Dağılımı

Atreca nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:0C1 Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 23	-98	36	45
30 Jun 23	-85	38	51
31 Mar 23	-93	39	58
31 Dec 22	-97	39	62
30 Sep 22	-105	40	68
30 Jun 22	-110	41	70
31 Mar 22	-108	43	67
31 Dec 21	-109	43	67
30 Sep 21	-103	42	61
30 Jun 21	-98	42	59
31 Mar 21	-92	38	55
31 Dec 20	-86	37	52
30 Sep 20	-83	37	50
30 Jun 20	-76	33	48
31 Mar 20	-74	29	50
31 Dec 19	-67	24	49
30 Sep 19	-59	17	48
30 Jun 19	-53	13	43
31 Mar 19	-44	11	35
31 Dec 18	-38	9	31

Kaliteli Kazançlar: 0C1 is currently unprofitable.

Büyüyen Kar Marjı: 0C1 is currently unprofitable.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0C1 is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Büyüme Hızlandırma: Unable to compare 0C1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: 0C1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).

Özkaynak Getirisi

Yüksek ROE: 0C1 has a negative Return on Equity (-908.6%), as it is currently unprofitable.

This company listing is no longer active

Atreca Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day high: €16.00

New 90-day low: €10.50

New 90-day high: €13.60

New 90-day low - €10.50

New 90-day low - €12.70

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin